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Abstract 
Background: Methylphenidate-based designer drugs are new psychoactive substances (NPS) 
that are used outside medical settings and their pharmacology is largely unexplored. The aim 
of the present study was to characterize the pharmacology of methylphenidate-based 
substances in vitro. 
Methods: We determined the potencies of the methylphenidate-based NPS N-
benzylethylphenidate, 3,4-dichloroethylphenidate, 3,4-dichloromethylphenidate, 
ethylnaphthidate, ethylphenidate, 4-fluoromethylphenidate, isopropylphenidate, 4-
methylmethylphenidate, methylmorphenate, and propylphenidate and the potencies of the 
related compounds cocaine and modafinil with respect to norepinephrine, dopamine, and 
serotonin transporter inhibition in transporter-transfected human embryonic kidney 293 cells. 
We also investigated monoamine efflux and monoamine receptor and transporter binding 
affinities. Furthermore, we assessed the cell integrity under assay conditions. 
Results: All methylphenidate-based substances inhibited the norepinephrine and dopamine 
transporters 4 to >1,000-fold more potently than the serotonin transporter. Similar to 
methylphenidate and cocaine, methylphenidate-based NPS did not elicit transporter-mediated 
efflux of monoamines.  Besides binding to monoamine transporters, several test drugs had 
affinity for adrenergic, serotonergic, and rat trace amine-associated receptors but not for 
dopaminergic or mouse trace amine-associated receptors. No cytotoxicity was observed after 
drug treatment at assay concentrations. 
Conclusion: Methylphenidate-based substances had pharmacological profiles similar to 
methylphenidate and cocaine. The predominant actions on dopamine transporters vs. 
serotonin transporters may be relevant when considering abuse liability. 
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Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); DA, dopamine; DAT, dopamine 
transporter; FLIPR, fluorescence imaging plate reader; HPLC, high-performance liquid 
chromatography; MDMA, 3,4-methylenedioxymethamphetamine; MPH, methylphenidate; 
NE, norepinephrine; NET norepinephrine transporter; NPS, new psychoactive substances; 
SERT, serotonin transporter; TAAR, trace amine-associated receptor. 
 
1. Introduction 
 The psychostimulant methylphenidate (MPH; Ritalin®) is used for the treatment of 
attention-deficit/hyperactivity disorder and narcolepsy but it also has a history of being 
misused as a ‘smart drug’ and ‘cognitive enhancer’ (Arria et al., 2008; Liakoni et al., 2015; 
Maier et al., 2013). In recent years, an increasing number of MPH-based new psychoactive 
substances (NPS; Fig. 1) (Brandt et al., 2014) have become available as alternatives to MPH 
(Bailey et al., 2015; European Monitoring Centre for Drugs and Drug Addiction, 2015) and 
have been associated with several fatalities (Krueger et al., 2014; Maskell et al., 2016; Parks 
et al., 2015). Characteristic for the NPS phenomenon, many of the currently circulating MPH 
analogs originated from drug development efforts (Deutsch et al., 1996; Markowitz et al., 
2013; Misra et al., 2010), which subsequently appeared on the streets. The pharmacological 
and subjective-effect profiles of MPH are very similar to cocaine (Simmler et al., 2014; 
Vogel et al., 2016; Volkow et al., 1999). Furthermore, some of these substances are either 
sold in their own right or offered in the form of branded products (Bailey et al., 2015; Parks 
et al., 2015). Methylphenidate predominantly inhibits the norepinephrine (NE) and dopamine 
(DA) transporters (NET and DAT, respectively), thus, possibly contributing to its abuse 
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potential (Simmler et al., 2014; Vogel et al., 2016). Correspondingly, questions arise about 
the extent to which MPH analogs might share MPH-like characteristics. Assessing the 
pharmacological profile of NPS in vitro is an initial step to gain a better understanding of the 
potential clinical effects and toxicology of these substances. For this reason, the present study 
reports on the transporter interaction profiles of the MPH-related NPS N-
benzylethylphenidate, 3,4-dichloroethylphenidate, 3,4-dichloromethylphenidate, and 
isopropylphenidate and the transporter and receptor interaction profiles of ethylnaphthidate, 
ethylphenidate, 4-fluoromethylphenidate, 4-methylmethylphenidate, methylmorphenate, and 
propylphenidate. Modafinil, a stimulant prescribed for the treatment of narcolepsy, which is 
frequently offered for sale as a ‘neuroenhancer’ (Ghahremani et al., 2011; Maier et al., 2013; 
Mereu et al., 2013; Müller et al., 2013), has also been included in this investigation. 
Stimulants may act as transporter inhibitors or as transporter substrates that cause monoamine 
efflux into the synaptic cleft (Rothman and Baumann, 2003; Sitte and Freissmuth, 2015). 
Therefore, additionally to the transporter inhibition potencies of the substances, their 
mechanism of action (reuptake inhibitor or transporter substrate) was determined. 
 
2. Material and methods 
2.1. Drugs 
 Cocaine, 3,4-methylenedioxymethamphetamine (MDMA) and MPH were purchased 
from Lipomed (Arlesheim, Switzerland), with high-performance liquid chromatography 
(HPLC) purity > 98.5%. Modafinil was purchased from Cayman Chemicals (Ann Arbor, MI, 
USA), with purity > 98%. Methylmorphenate and propylphenidate were obtained from 
reChem Labs (Ontario, Canada) and afterwards identified and tested for purity using nuclear 
magnetic resonance (NMR) and HPLC, which revealed purity > 95%. N-
Benzylethylphenidate, 3,4-dichloroethylphenidate, 3,4-dichloromethylphenidate, 
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ethylnaphthidate, 4-fluoromethylphenidate, isopropylphenidate, and 4-
methylmethylphenidate were part of confiscations by German authorities and test purchases 
(Klare et al., 2017). The substances were fully characterized in a previous study (Klare et al., 
2017) and purity values were estimated at > 95% based on spectroscopic and 
chromatographic methods of analysis. Ethylphenidate was provided by Dr. Christian Bissig 
(Forensic Institute, Zurich, Switzerland) after being confiscated by Swiss authorities and 
being tested for purity of > 98%. Modafinil was obtained as racemic base. The other drugs 
were obtained as racemic hydrochloride salts. Radiolabeled [3H]-NE (13.1 Ci/mmol) and 
[3H]-DA (30.0 Ci/mmol) were obtained from Perkin-Elmer (Schwerzenbach, Switzerland). 
Radiolabeled [3H]-5-HT (80 Ci/mmol) was purchased from Anawa (Zürich, Switzerland). 
 
2.2. Monoamine uptake transport inhibition 
 Monoamine uptake inhibition was assessed using human embryonic kidney (HEK) 
293 cells that stably expressed the human SERT, DAT, or NET (Tatsumi et al., 1997) as 
previously described (Hysek et al., 2012). Briefly, the cells were cultured to 70-90% 
confluence, detached, and resuspended in Krebs-Ringer Bicarbonate Buffer (Sigma-Aldrich, 
Buchs, Switzerland). For [3H]-DA uptake experiments, the uptake buffer was supplemented 
with 1.14 mM ascorbic acid. The cells were then treated with vehicle control and drug in the 
range of 1 nM to 900 µM for 10 min at room temperature. Additionally, monoamine-specific 
inhibitors were added (10 µM fluoxetine for SERT, 10 µM mazindol for DAT, and 10 µM 
nisoxetine for NET). To initiate uptake transport, [3H]-5-HT, [3H]-DA, or [3H]-NE were 
added at a final concentration of 5 nM for an additional 10 min. The cells were then separated 
from the uptake buffer by centrifugation through silicone oil, and the tubes were frozen in 
liquid nitrogen. The cell pellet was cut into scintillation vials and lysed. The samples were 
shaken for 1 h before scintillation fluid (Ultimagold, Perkin Elmer, Schwerzenbach, 
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Switzerland) was added. Monoamine uptake was then quantified by liquid scintillation 
counting on a Packard Tri-Carb Liquid Scintillation Counter 1900 TR. Uptake in the 
presence of the selective inhibitors was determined to be nonspecific and subtracted from the 
total counts. 
 
2.3. Transporter-mediated monoamine efflux 
The potential of the drugs to initiate transporter-mediated NE, DA, or 5-HT efflux 
was assessed in HEK 293 cells that overexpressed the respective transporter as previously 
described (Simmler et al., 2013). Briefly, the cells were first preloaded with [3H]-NE, [3H]-
DA, or [3H]-5-HT dissolved in Krebs-HEPES buffer for 20 min at 37ºC. The cells were then 
washed and treated with 100 µM of the drugs for 15 min (DAT and SERT) or 45 min (NET). 
The treatment durations for [3H]-NE, [3H]-DA, and [3H]-5-HT efflux experiments were based 
on kinetic evaluation of the efflux-over-time curves of MDMA (Simmler et al., 2014). The 
cells were washed again, and the remaining radioactivity inside the cells was quantified. The 
monoamine transporter blockers citalopram (SERT), mazindol (DAT), and nisoxetine (NET) 
were added as a negative control at a concentration of 10 µM to determine “pseudo-efflux” 
that was caused by nonspecific monoamine efflux and subsequent reuptake inhibition 
(Scholze et al., 2000). 
 
2.4. Radioligand receptor and transporter binding assays 
 The radioligand binding assays were performed as previously described for 
transporters (Hysek et al., 2012) and receptors (Revel et al., 2011). Briefly, membrane 
preparations of HEK 293 cells (Invitrogen, Zug, Switzerland) that overexpressed the 
respective transporters (Tatsumi et al., 1997) or receptors (human genes, with the exception 
of rat and mouse genes for trace amine-associated receptors [TAARs]) (Revel et al., 2011) 
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were incubated with the radiolabeled selective ligands at concentrations equal to Kd, and 
ligand displacement by the compounds was measured. Specific binding of the radioligand to 
the target receptor was defined as the difference between the total binding and nonspecific 
binding that was determined in the presence of the selected competitors. The following 
radioligands and competitors, respectively, were used: N-methyl-[3H]-nisoxetine and 10 µM 
indatraline (NET), [3H]citalopram and 10 µM indatraline (SERT), [3H]WIN35,428 and 10 
µM indatraline (DAT), [3H]8-hydroxy-2-(di-n-propylamine)tetralin and 10 µM pindolol (5-
HT1A receptor), [3H]ketanserin and 10 µM spiperone (5-HT2A receptor), [3H]mesulgerine and 
10 µM mianserin (5-HT2C receptor), [3H]prazosin and 10 µM chlorpromazine (α1A adrenergic 
receptor), [3H]rauwolscine and 10 µM phentolamine (α2A adrenergic receptor), [3H]spiperone 
and 10 µM spiperone (D2 receptor), and [3H]RO5166017 and 10 µM RO5166017 (TAAR1). 
 
2.5. Activity at the serotonin 5-HT2B receptor 
 Activity at the 5-HT2B receptor was assessed as previously described (Rickli et al., 
2016). Briefly, human 5-HT2B receptor-expressing HEK 293 cells were incubated in a cell 
culture plate overnight. The next day, the growth medium was removed by snap inversion, 
and calcium indicator Fluo-4 solution (Molecular Probes, Eugene, OR, USA) was added to 
each well. The plates were then incubated for 45 min at 31ºC. The Fluo-4 solution was 
removed by snap inversion and then added a second time. The cells were then incubated for 
another 45 min at 31ºC. Immediately before testing, the cells were washed with HBSS and 20 
mM HEPES (assay buffer; Gibco) using an EMBLA cell washer, and assay buffer was 
added. The plates were placed in a FLIPR. Test substances that were diluted in assay buffer 
were added online, and the increase in fluorescence was measured. 
 
2.6. Cytotoxicity 
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 Cytotoxicity was assessed with the ToxiLight bioassay kit (Lonza, Basel, 
Switzerland) according to the manufacturer’s protocol. The kit measures adenylate kinase 
release as a result of cell membrane integrity loss. Human SERT-, DAT-, and NET-
transfected HEK 293 cells were treated for 1 h at room temperature with the drugs at the 
highest assay concentrations. 
 
2.7. Statistical analysis 
Calculations were performed using Prism 7.0a software (GraphPad, San Diego, CA, 
USA). Monoamine transporter inhibition data were fit by nonlinear regression to variable-
slope sigmoidal dose-response curves and IC50 values were assessed. The DAT/SERT ratio is 
expressed as 1/DAT IC50:1/SERT IC50. Compound-induced monoamine efflux of five 
independent experiments was compared with negative controls using analysis of variance 
followed by the Holm-Sidak test. P values lower than 0.05 were considered significant and 
substances were considered transporter substrates if they caused significantly higher efflux 
than the negative controls. IC50 values of radioligand binding were determined by calculating 
nonlinear regression curves for a one-site model using three independent 10-point 
concentration-response curves for each compound. Ki (affinity) values, which correspond to 
the dissociation constants, were determined using the Cheng-Prusoff equation. Nonlinear 
regression concentration-response curves were used to calculate the EC50 values for the 5-
HT2B receptor activation. 
 
3. Results 
3.1. Monoamine uptake transporter inhibition 
Monoamine uptake inhibition curves are shown in Fig. 2, and the corresponding IC50 
values and DAT/SERT inhibition ratios are listed in Table 1. Methylphenidate was a potent 
9 	  
inhibitor of the NET and DAT at submicromolar concentrations and a weak inhibitor of the 
SERT. 3,4-dichloromethylphenidate inhibited the NET more than 10-fold more potently than 
MPH, whereas the inhibition potency for the DAT was more than 2-fold increased. The NET 
and DAT inhibition potencies of 3,4-dichloroethylphenidate, ethylnaphthidate, 4-
fluoromethylphenidate, and 4-methylmethylphenidate were similar to MPH in the range of 
0.04–0.42 µM for the NET and 0.08–0.34 µM for the DAT. N-Benzylethylphenidate, 
ethylphenidate, isopropylphenidate, methylmorphenate, and propylphenidate inhibited the 
NET with 6 to 800-fold lower potency compared to MPH and the DAT with 4 to 500-fold 
lower potency. The SERT inhibition potency for all MPH-based NPS was lower than the 
NET and DAT inhibition potencies. Ethylnaphthidate inhibited the SERT at 1.7 µM with a 
DAT/SERT ratio of 5. The remaining compounds inhibited the SERT 40 to >1000-fold 
weaker than the DAT and 26 to >1000-fold weaker than the NET. Modafinil was a weak 
inhibitor of monoamine transporters with an IC50 value >10 µM for the DAT and no relevant 
NET or SERT inhibition (IC50 values >100 µM). Unlike the MPH-based substances and 
modafinil, cocaine inhibited all three transporters with similar potency in the range of 0.5–1.5 
µM. 
 
3.2. Monoamine efflux 
 Similar to cocaine, MPH and the MPH-based NPS and related compounds did not 
cause monoamine efflux  (Fig. 3) and are therefore not transporter substrates. 
 
3.3. Monoamine receptor and transporter binding affinities 
 The interactions between MPH-based NPS and related compounds with monoamine 
receptors and transporters are shown in Table 2. All MPH-based NPS bound to the NET and 
DAT but only N-benzylethylphenidate, 3,4-dichloroethylphenidate, 3,4-
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dichloromethylphenidate, and ethylnaphthidate bound to the SERT in the concentration range 
tested. 3,4-Dichloroethylphenidate, 3,4-dichloromethylphenidate, 4-methylmethylphenidate, 
and ethylnaphthidate bound to the α1A receptor in the range of 1.7–6.5 µM and additionally to 
the α2A receptor in the range of 7–10 µM. Ethylphenidate and propylphenidate bound to the 
α2A receptor with 14 µM and 8.7 µM, respectively, but did not bind to the α1A receptor in the 
investigated concentration range. 3,4-Dichloroethylphenidate, 3,4-dichloromethylphenidate, 
ethylnaphthidate, 4-methylmethylphenidate, and propylphenidate, had affinities of 1–17 µM 
for the 5-HT1A receptor. Ethylnaphthidate was the only drug to bind to the 5-HT2A receptor 
with an IC50 value of 4.9 µM and only 3,4-dichloromethylphenidate and ethylnaphthidate 
bound to the 5-HT2C receptor, both with an IC50 of 12 µM. None of the compounds activated 
the 5-HT2B receptor or bound to the mouse TAAR1, and only 3,4-dichloroethylphenidate, 3,4-
dichloromethylphenidate, and isopropylphenidate bound to the rat TAAR1 with affinities in 
the range of 6–13 µM. None of the MPH-based NPS had relevant affinity for D2 receptors. 
Modafinil and cocaine bound to the monoamine transporters but did not interact with 
monoamine or trace amine receptors. 
 
3.4. Cytotoxicity 
 Cytotoxicity was not observed for any of the drugs in the functional assays at the 
concentrations tested, thus confirming cell integrity during the assays. 
 
4. Discussion 
 We characterized the in vitro pharmacological profiles of MPH-based NPS and 
compared them with MPH and cocaine. All compounds inhibited the DAT substantially more 
potently than the SERT, suggesting predominantly stimulant-type effects similar to 
amphetamine and a high abuse liability (Liechti, 2015; Simmler et al., 2013).  
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4.1. Monoamine uptake transporter inhibition and monoamine efflux 
 Methylphenidate and MPH-based NPS, with the exception of N-
benzylethylphenidate, isopropylphenidate, and methylmorphenate, inhibited the NET at 
submicromolar concentrations, suggesting cardiostimulant and psychostimulant properties, 
similar to amphetamines (Hysek et al., 2011; Simmler et al., 2013). Moreover, the NET and 
DAT inhibition potencies but not the SERT inhibition potency correlate with the 
psychotropic effective doses of psychostimulants in human (Simmler et al., 2013). 
The MPH-based NPS were only monoamine transporter inhibitors and not 
monoamine transporter substrates, indicating a mechanism of action similar to cocaine but 
not amphetamines (Fleckenstein et al., 2007; Torres et al., 2003). Ethylnaphthidate inhibited 
the SERT at low micromolar concentrations, but the remaining MPH-based NPS displayed a 
clear preference for DAT over SERT, resulting in high DAT/SERT ratios frequently reported 
for locomotor stimulants (Simmler et al., 2013). Our results are consistent with other studies 
that reported potent NET and DAT inhibition for MPH (DAT/SERT ratio = 2207) and triple 
uptake inhibition for cocaine (DAT/SERT ratio = 3.2) (Han and Gu, 2006). Modafinil was a 
moderate and relatively selective DAT inhibitor, with an IC50 value of 11 µM. This finding is 
consistent with previous in vitro studies that reported IC50 values of 4–13 µM (Karabacak et 
al., 2015; Loland et al., 2012; Madras et al., 2006; Zolkowska et al., 2009). The interaction 
between modafinil and DAT is also thought to modulate the pharmacological effects of the 
drug (Wisor, 2013). The psychopharmacological profiles and cognitive-enhancing properties 
of MPH and modafinil may be different. Modafinil has been shown to improve attention and 
wakefulness, whereas MPH has been shown to improve memory (Repantis et al., 2010). 
 
4.2. Transporter and receptor binding profiles 
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 Compared with ethylphenidate, replacement of the benzene ring with naphthalene 
(ethylnaphthidate) increased the potency in inhibiting the SERT and increased the affinity for 
5-HT receptors. Many stimulant NPS interact with TAARs (Simmler et al., 2016); however, 
no potent TAAR interactions were found for MPH-based NPS. 3,4-Dichloromethylphenidate 
and ethylnaphthidate interacted with the α1A and 5-HT1A receptor in the low micromolar 
range. The remaining MPH-based NPS did not potently interact with monoamine receptors, 
indicating that they exert their primary effects by inhibiting uptake transporters, similar to 
MPH and cocaine (Ritz et al., 1987, 1988; Volkow et al., 2002).  Consistent with the 
monoamine uptake data, 3,4-dichloroethylphenidate, 3,4-dichloromethylphenidate, and 
ethylnaphthidate potently bound to the NET and DAT and had affinity for the SERT as well. 
4-Fluoromethylphenidate, 4-methylmethylphenidate, and methylphenidate bound potently to 
the NET and DAT but had no affinity to the SERT in the tested concentration range. N-
Benzylethylphenidate, ethylphenidate, isopropylphenidate, and propylphenidate showed high 
affinity for the DAT but not for the NET or SERT. Methylmorphenate did not potently bind 
to any transporter. Cocaine potently bound to all transporters but not to receptors. No 
interaction between modafinil and monoamine receptors was observed. To date, no single site 
of action for modafinil has been identified (Gerrard and Malcolm, 2007). 
 
4.3. Comparison of transporter binding and transporter inhibition 
 No drug-mediated monoamine efflux was observed for any of the MPH-based 
compounds, strengthening the argument that they are pure uptake blockers. 
For uptake blockers, a correlation between the monoamine uptake and radioligand binding 
affinities has been previously described for the NET (Cheetham et al., 1996; Lee et al., 1982), 
the DAT (Javitch et al., 1984; Schoemaker et al., 1985), and the SERT (D'Amato et al., 1987; 
Langer et al., 1980). However, discrepancies between monoamine uptake inhibition and 
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radioligand binding have been observed for cocaine-like drugs and proposed for MPH-like 
drugs, when the conditions for the binding and uptake inhibition assays varied (Reith et al., 
2005; Rothman et al., 1993). 
Highest NET and DAT binding affinities were observed for the most potent NET and 
DAT inhibitor 3,4-dichloromethylphenidate. However, the increase in potency compared to 
MPH was much more pronounced with a 76-fold and 12-fold increase for NET and DAT 
binding, respectively. 3,4-Dichloroethylphenidate bound more than 10-fold more potently to 
the NET and DAT whereas the NE and DA uptake inhibition was similar to MPH. 
Ethylnaphthidate, 4-fluoromethylphenidate, and 4-methylmethylphenidate inhibited the NET 
and DAT with similar potency as MPH. These substances bound to the NET with affinity in 
the range of 0.22–0.31 µM and to the DAT with affinity in the range of 0.026–0.040 µM. 
MPH bound to the NET and DAT with 0.50 µM and 0.070 µM, respectively. Thus, unlike for 
the dichloro substituted compounds, the IC50 values and the Ki values for ethylnaphthidate, 4-
fluoromethylphenidate, and 4-methylmethylphenidate correlate well. N-
Benzylethylphenidate, ethylphenidate, isopropylphenidate, methylmorphenate, and 
propylphenidate inhibited the NET with 6 to 800-fold lower potency compared to MPH and 
the DAT with 4 to 500-fold lower potency. While the binding affinities for the NET were 8 to 
48-fold decreased, the DAT binding affinities were decreased only for N-
benzylethylphenidate, methylmorphenate, and propylphenidate (5 to 46-fold) whereas the 
DAT binding affinites of ethylphenidate and isopropylphenidate were close to MPH. 
Remarkably, N-benzylethylphenidate was by far the weakest transporter inhibitor, it did 
however not have the lowest NET and DAT binding affinities. In the investigated 
concentration range, only N-benzylethylphenidate, 3,4-dichloroethylphenidate, 3,4-
dichloromethylphenidate, and ethylnaphthidate bound to the SERT. 3,4-
dichloroethylphenidate, 3,4-dichloromethylphenidate, and ethylnaphthidate, were the most 
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potent SERT inhibitors, N-benzylethylphenidate was however the weakest SERT inhibitor. 
Thus, as observed for the NET and DAT, the SERT binding affinity of N-
benzylethylphenidate was much higher than might be expected from the uptake inhibition 
data. 
To conclude, the rank order of potency of the radioligand binding and uptake 
inhibition was similar with the 3,4-substituted and 4-substitued compounds being among the 
most potent MPH-based NPS; the relative potencies of the uptake inhibition and transporter 
binding varied however to a certain extent. 
Besides cocaine, ethylnaphthidate was the only compound to have considerable 
inhibition potencies and affinities for all transporters. The inhibition and binding potencies 
generally decreased with increasing size of the carbon side chain. Compared to MPH, the 
steric ring-substitution of N-benzylethylphenidate substantially decreased the inhibition 
potency for all transporters and the binding to the NET and DAT. However, higher binding 
affinity for the SERT was observed. Modafinil selectively inhibited and bound to the SERT. 
The present study has limitations. Possible potent contaminants could theoretically 
have influenced the results for some drugs with lower purity. Substance-induced efflux was 
only tested at a high substance concentration. The absence of monoamine efflux could be the 
result of bell-shaped concentration-efflux curves as it has been demonstrated for 
amphetamine analogs with known monoamine releasing properties, including MDMA, in 
different in vitro assays (Seidel et al., 2005). However, such bell-shaped efflux curves were 
not observed in the assay used in the present study as previously documented (Hysek et al., 
2012), strengthening the argument that the MPH-based NPS are in fact pure uptake 
inhibitors. Moreover, in this study the focus was laid on the NET, DAT, and SERT, as they 
are main targets of amphetamines and presumably many stimulant NPS (Sitte and 
Freissmuth, 2015). Other possible mechanisms that may contribute to the effects of NPS, 
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such as VMAT2 inhibition (Sulzer et al., 2005), calcium-triggered exocytosis of monoamines 
(Mundorf et al., 1999; Sulzer et al., 2005), mRNA regulation (Douglass et al., 1995), or ion 
channel blockage (Bauman and DiDomenico, 2002; O'Leary and Hancox, 2010), were not 
investigated in this study. 
 
5. Conclusion 
 Similar to MPH and cocaine, MPH-based NPS are potent inhibitors of the NET and 
DAT. Furthermore, they are not monoamine transporter substrates and have only minor 
interactions with monoamine receptors. The high selectivity for the DAT vs. SERT suggests 
that these emerging drugs may have abuse potential. Modafinil is a weak but selective 
inhibitor at DAT but does not present monoamine receptor interactions. 
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Figures 
 
Fig. 1. Chemical structures of MPH-based NPS and related compounds. 
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Fig. 2. Monoamine uptake inhibition in stably transfected HEK 293 cells that expressed the 
human NET, DAT, or SERT. Curves were fitted by non-linear regression, and corresponding 
IC50 values are shown in Table 1. The data are presented as the mean ± SEM and numbers in 
parentheses indicate the number of individual experiments performed in triplicate 
(NET/DAT/SERT): N-benzylethylphenidate (4/4/4), 3,4-dichloroethylphenidate (3/3/5), 3,4-
dichloromethylphenidate (3/3/4), ethylnaphthidate (3/3/3), ethylphenidate (3/3/5), 4-
fluoromethylphenidate (4/4/4), isopropylphenidate (3/3/4), 4-methylmethylphenidate (4/3/4), 
methylmorphenate (3/3/4), methylphenidate (3/3/6), propylphenidate (3/3/4), cocaine (3/4/5), 
modafinil (6/7/6). 
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Fig. 3. Monoamine efflux induced by 100 µM of the compounds after preloading HEK 293 
cells that expressed the human NET, DAT, or SERT with radiolabeled monoamine. The 
efflux is expressed as percentage of [3H]-NE, [3H]-DA, or [3H]-5-HT decrease in monoamine 
preloaded cells compared to vehicle control. The dashed line marks nonspecific “pseudo-
efflux” that arises from monoamine diffusion and subsequent reuptake inhibition. Substances 
that caused significantly more monoamine efflux (*p < 0.05) than pure uptake inhibitors 
(open bars) were determined to be monoamine transporter substrates. The data are presented 
as the mean ± SEM of five independent experiments. 
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Tables 
 
Table 1. Monoamine transport inhibition. 
	   	   	   	    NET DAT SERT DAT/SERT  
	    IC50 [µM] (95% CI) IC50 [µM] (95% CI) IC50 [µM] (95% CI) ratio (95% CI) 
	  Methylphenidate-based     
	  Methylphenidate 0.12 (0.09–0.16) 0.13 (0.10–0.18) 274 (204–366) 2108 (1133–3660) 
	  4-Methylmethylphenidate 0.09 (0.07–0.11) 0.15 (0.12–0.18) 164 (132–204) 1093 (733–1700) 
	  Ethylphenidate 0.81 (0.62–1.06) 0.61 (0.45–0.84) 257 (205–322) 421 (244–716) 
	  4-Fluoromethylphenidate 0.04 (0.03–0.06) 0.15 (0.12–0.20) 40 (33–48) 267 (165–400) 
	  3,4-Dichloromethylphenidate 0.01 (0.01–0.02) 0.05 (0.04–0.06 12 (9–15) 240 (150–375) 
	  Isopropylphenidate 2.3 (1.8–2.9) 0.82 (0.68–1.00) 147 (112–193) 179 (112–284) 
	  Methylmorphenate 9.3 (7.0–12.3) 13 (11–16) 1831 (932–3600) 141 (58–327) 
	  3,4-Dichloroethylphenidate 0.13 (0.10–0.16) 0.08 (0.06–0.09) 8.0 (6.9–9.3) 100 (77–155) 
	  Propylphenidate 0.94 (0.71–1.25) 1.2 (1.0–1.6) 84 (67–106) 70 (42–106) 
	  N-Benzylethylphenidate 95 (59–154) 60 (41–86) 2515 (958–6605) 42 (11–161) 
	  Ethylnaphthidate 0.42 (0.32–0.54) 0.34 (0.28–0.42) 1.7 (1.3–2.1) 5.0 (3.1–7.5) 
	  Other     
	  Modafinil 231 (177–300) 11 (9–14) 2616 (250–27300) 238 (28–1950) 
	  Cocaine 0.48 (0.36–0.64) 0.90 (0.75–1.08) 1.5 (1.2–1.9) 1.7 (1.1–2.5) 
	  Values are means and 95% confidence intervals (CI). DAT/SERT ratio = 1/DAT IC50 : 1/SERT IC50. 	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Table 2. Monoamine transporter and receptor binding affinities.	  
  NET DAT SERT D2 α1A α2A 5-HT1A 5-HT2A 5-HT2B 5-HT2C TA1rat TA1mouse 
  Ki Ki Ki Ki Ki Ki Ki Ki EC50 Ki Ki Ki 
Methylphenidate-based             
Methylphenidate 0.50±0.17 0.070±0.020 >22 >4.4 >8.9 >15 >17 >13 >10 >15 >5.0 >4.7 
4-Methylmethylphenidate 0.31±0.10 0.033±0.007 >22 >4.4 6.5±0.3 10±1 9.9±0.7 >13 >10 >15 >5.0 >4.7 
Ethylphenidate 4.9±0.7 0.081±0.007 >30 >25 >12 14±1 >25 >12 >20 >15 >15a >15a 
4-Fluoromethylphenidate 0.22±0.08 0.040±0.007 >22 >4.4 >8.9 >15 >17 >13 >10 >15 >5.0 >4.7 
3,4-Dichloromethylphenidate 0.0066±0.0006 0.0060±0.0005 3.0±0.1 >4.4 1.7±0.1 7.0±0.6 1.8±0.1 >13  >15 6.2±0.6 >14 
Isopropylphenidate 4.2±0.4 0.097±0.014 >23 >4.4 >11 >15 >17 >13  >15 13±2 >14 
Methylmorphenate 24±1 3.2±0.3 >22 >4.4 >8.9 >15 >17 >13 >10 >15 >5.0 >4.7 
3,4-Dichloroethylphenidate 0.028±0.003 0.0065±0.0002 1.5±0.2 >4.4 4.3±0.1 7.5±0.3 4.5±0.4 >13  12±0.3 6.6±1.3 >14 
Propylphenidate 3.8±1.3 0.33±0.07 >22 >4.4 >8.9 8.7±0.5 17±1 >13 >10 >15 >5.0 >4.7 
N-Benzylethylphenidate 5.5±0.5 0.33±0.01 8.4±1.0 >4.4 >11 >15 >17 >13  >15 >15 >14 
Ethylnaphthidate 0.27±0.06 0.026±0.003 0.58±0.05 >4.4 1.8±0.2 8.6±0.5 1.3±0.2 4.9±0.5 >10 12±3 >5.0 >4.7 
Other 
	   	   	   	   	   	   	   	   	   	   	   	  Modafinil >26 4.0±0.7 >22 >4.4 >8.9 >15 >17 >13 >10 >15 >5.0 >4.7 
Cocaine 1.6±0.3 0.20±0.02 0.87±0.04 >4.4 >8.9 >15 >17 >13 >10 >15 >5.0 >4.7 
Values are given as µM (mean±SD). 
	   	   	   	   	   	   	   	   	   	   	  aFrom Simmler et al., 2016 
	   	   	   	   	   	   	   	   	   	   	   	   
